Biotech IPOs Jump More Than 20% as Momentum Builds for Listings
(Bloomberg) -- Drug developers are capitalizing on the industry’s momentum by tapping public investors for the first time, as corporate takeovers and a welcoming market lift optimism about biotechnology.Most Read from BloombergCitadel Among Hedge Funds That Got Morgan Stanley’s Block-Trading LeaksTesla Asks Which Jobs Are Critical, Stoking Layoff FearsChina Replaces Top Markets Regulator as Xi Tries to End RoutUS Commercial Real Estate Contagion Is Now Moving to EuropeHaley Loses Nevada Primary
Source: yahoo.com